Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Howard Capital Management Inc.

Howard Capital Management Inc. grew its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 47.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,949 shares of the biopharmaceutical company's stock after purchasing an additional 6,416 shares during the quarter. Howard Capital Management Inc.'s holdings in Bristol-Myers Squibb were worth $1,128,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Wealthspire Advisors LLC increased its position in Bristol-Myers Squibb by 0.6% during the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock worth $1,622,000 after buying an additional 170 shares in the last quarter. Kooman & Associates purchased a new stake in Bristol-Myers Squibb during the 4th quarter worth about $209,000. TCW Group Inc. raised its stake in Bristol-Myers Squibb by 2.0% in the 4th quarter. TCW Group Inc. now owns 37,339 shares of the biopharmaceutical company's stock valued at $2,112,000 after purchasing an additional 721 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in Bristol-Myers Squibb by 2.8% in the 4th quarter. First Horizon Advisors Inc. now owns 406,458 shares of the biopharmaceutical company's stock valued at $22,989,000 after purchasing an additional 11,072 shares in the last quarter. Finally, Lipe & Dalton boosted its stake in shares of Bristol-Myers Squibb by 0.4% during the 4th quarter. Lipe & Dalton now owns 56,769 shares of the biopharmaceutical company's stock worth $3,211,000 after purchasing an additional 208 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 1,823 shares of Bristol-Myers Squibb stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock opened at $55.85 on Monday. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The company has a market cap of $113.33 billion, a PE ratio of -12.63, a P/E/G ratio of 2.07 and a beta of 0.45. The company's fifty day simple moving average is $56.99 and its 200-day simple moving average is $54.41. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.10.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 4.44%. The ex-dividend date of this dividend was Friday, January 3rd. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.60. Bristol-Myers Squibb's dividend payout ratio is currently -56.11%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BMY. Truist Financial boosted their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Jefferies Financial Group upgraded Bristol-Myers Squibb from a "hold" rating to a "buy" rating and boosted their price target for the company from $63.00 to $70.00 in a report on Monday, December 16th. Morgan Stanley raised their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an "underweight" rating in a report on Tuesday, November 12th. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a research note on Wednesday, November 13th. Finally, Bank of America reissued a "neutral" rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb has an average rating of "Hold" and an average price target of $57.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.